Jakarta, CNBC Indonesia – Indonesia promises to reduce dependence on imported Covid-19 vaccines by making the Red and White Vaccine. What will happen to this program?
Coordinating Minister for Economic Affairs Airlangga Hartarto revealed the development of the Red and White Vaccine and BUMN Vaccine. The Red and White Vaccine in collaboration with Universitas Airlangga (UNAIR) and PT Biotis is now awaiting approval for phase 1 clinical trials from BPOM in December 2021.
“Clinical trials for phases 2 and 3 will take place from January to June 2022. Emergency Use Authorization or an emergency use permit (UAE) and the Fatwa of the Indonesian Ulema Council (MUI) are estimated for the third quarter of 2022,” said Airlangga Hartarto in an official statement, Monday (27/12). /2021).
The Red and White Vaccine in collaboration with LBM Eijkman and Bio Farma is still in the pre-clinical testing stage and waiting for the industrial CPOB facility. The EUA and the MUI fatwa are expected in the fourth quarter of 2022.
The BUMN vaccine in collaboration with Bio Farma and Baylor College of Medicine has started phase 1 clinical trials on December 13. This vaccine has been registered in the Emergency Use of Listing on June 8, 2021. The EUA and the MUI Fatwa are estimated to be completed in July 2022. The production capacity is 75 – 150 million doses from June to December 2022.
Another BUMN vaccine, GX-19 (Kalbe Farma & Genexine) is in the Phase 3 Clinical Trial stage and is reporting a Clinical Trial to get EUA, EUA & MUI Fatwa is expected in early 2022, production capacity of 50 Million Doses (June – December 2022).
“The Zifivax vaccine (JBio & Anhui Zhifei) has completed Phase 3 Clinical Trials, is preparing a joint production facility for Biotis in Serang, Banten, EUA for ages 18-59 years has been around since October 7, 2021, and halal fatwa from MUI No. 35/ 2021, production capacity of 150 million doses in 2022,” explained Airlangga.
Information only, the Red and White Vaccine and BUMN vaccine will make Indonesia not dependent on imported vaccines. Currently, the Covid-19 vaccine that is licensed for use in Indonesia is an imported vaccine. The vaccines are Sinovac (China), Moderna (US), Pfizer (US), AstraZeneca (Europe), Sinopharm (China) to Sputnik V (Russia).
(roy/roy)
– .
